✦ LIBER ✦

Influence of first-line chemotherapy and EGFR mutations on second-line gefitinib in advanced non-small cell lung cancer

✍ Scribed by Wu, Jenn-Yu; Yu, Chong-Jen; Shih, Jin-Yuan; Yang, Chih-Hsin; Yang, Pan-Chyr

Book ID: 118238092
Publisher: Elsevier Science
Year: 2010
Tongue: English
Weight: 374 KB
Volume: 67
Category: Article
ISSN: 0169-5002
DOI: 10.1016/j.lungcan.2009.04.018

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

First-Line Gefitinib in Patients With Ad

First-Line Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer Harboring Somatic EGFR Mutations

✍ Sequist, L. V.; Martins, R. G.; Spigel, D.; Grunberg, S. M.; Spira, A.; Janne, P 📂 Article 📅 2008 🏛 American Society of Clinical Oncology 🌐 English ⚖ 228 KB

Second-line treatments after first-line

Second-line treatments after first-line gefitinib therapy in advanced nonsmall cell lung cancer

✍ Jenn-Yu Wu; Jin-Yuan Shih; Chih-Hsin Yang; Kuan-Yu Chen; Chao-Chi Ho; Chong-Jen 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 French ⚖ 236 KB

## Abstract Gefitinib is effective as first‐line therapy for advanced nonsmall cell lung cancer (NSCLC). However, after failure of gefitinib, it is unknown whether any second‐line regimens could lead to better outcomes. To study the influence of different second‐line antitumor regimens on the outco

First-Line Single Agent Treatment With G

First-Line Single Agent Treatment With Gefitinib in Advanced Non–Small-Cell Lung Cancer Patients

✍ Yong-mei Yin 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 37 KB

Gefitinib as first-line, compassionate u

Gefitinib as first-line, compassionate use therapy in patients with advanced non-small-cell lung cancer

✍ Argiris, Athanassios; Mittal, Namrata 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 90 KB

Gefitinib vs. chemotherapy as first-line

Gefitinib vs. chemotherapy as first-line therapy in advanced non-small cell lung cancer: Meta-analysis of phase III trials

✍ Ku, Geoffrey Y.; Haaland, Benjamin A.; de Lima Lopes, Gilberto 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 281 KB

PCN7 COMPARATIVE EFFECTIVENESS ASSESSMEN

PCN7 COMPARATIVE EFFECTIVENESS ASSESSMENT OF ERLOTINIB VERSUS GEFITINIB IN FIRST-LINE EGFR ACTIVATING MUTATION POSITIVE NON-SMALL CELL LUNG CANCER

✍ B. Schwander; J. de Castro Carpeño; D.F. Heigener; E. Wright; H.G. Bischoff; S. 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 55 KB